Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Expanding Anti-Corruption Drive Across Health Sector

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's ongoing battle to curtail corruption was the topic of PharmAsia News' Aug. 27 audioconference, "Anti-Bribery Compliance in China - Avoiding the Pitfalls."

You may also be interested in...



CEO Of China's Leading Vaccine Producer Reveals Latest Vaccine Scandal Has Triggered A Sector-wide Boycott, Throwing Firm Into The Red

BEIJING - The chief executive officer of Sinovac Biotech, China's leading vaccine developer, told investors this week that the country's latest vaccine scandal had poisoned public perceptions so deeply that many citizens are boycotting the entire sector

CEO Of China's Leading Vaccine Producer Reveals Latest Vaccine Scandal Has Triggered A Sector-wide Boycott, Throwing Firm Into The Red

BEIJING - The chief executive officer of Sinovac Biotech, China's leading vaccine developer, told investors this week that the country's latest vaccine scandal had poisoned public perceptions so deeply that many citizens are boycotting the entire sector

U.S. Regulators Beef Up Investigation of Corporate Bribery & Corruption Overseas

Pharmaceutical companies have been battered by government and congressional investigations of their domestic marketing practices. They now face increased scrutiny on another front as the Department of Justice and the Securities and Exchange Commission are stepping up investigations of corporate corruption and bribery abroad

Related Content

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel